Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-targeted CAR-T in B Cell Leukemia
NCT02672501Phase 2Unknown
- Sponsor
- Shanghai Genechem
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 CAR-T cells in B-cell leukemia (BCL), sponsored by Shanghai Genechem. Primary endpoint: Number of patients with adverse event at 6 weeks. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT02672501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672501.